Aspirin Use
Introduction
Aspirin, chemically known as acetylsalicylic acid, is a widely used nonsteroidal anti-inflammatory drug (NSAID) with a long history in medicine. Derived from compounds found in willow bark, it has been utilized for centuries in various forms before its modern synthesis. Today, aspirin is commonly taken for its analgesic (pain-relieving), antipyretic (fever-reducing), and anti-inflammatory properties.
Biological Basis
The primary biological basis for aspirin's effects lies in its irreversible inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By blocking these enzymes, aspirin prevents the synthesis of prostaglandins, which are lipid compounds involved in mediating pain, inflammation, and fever. Additionally, aspirin's inhibition of COX-1 in platelets reduces the production of thromboxane A2, a potent inducer of platelet aggregation. This antiplatelet effect is crucial for its role in cardiovascular health.
Clinical Relevance
Aspirin holds significant clinical relevance, particularly in the prevention and management of cardiovascular diseases. Low-dose aspirin regimens are widely prescribed for the primary prevention of cardiovascular disease and cancer, as demonstrated in randomized clinical trials. [1] Beyond cardiovascular health, aspirin remains a common over-the-counter medication for general pain relief, headaches, and inflammatory conditions. However, its antiplatelet effects necessitate careful consideration, and individuals taking aspirin are often excluded from analyses involving platelet aggregation phenotypes. [2]
Social Importance
Aspirin's accessibility, affordability, and broad therapeutic applications have made it one of the most frequently used medications globally. Its impact on public health is substantial, particularly in reducing the burden of cardiovascular disease. While generally effective, individual responses to aspirin can vary, and its use requires careful consideration of potential side effects, such as gastrointestinal bleeding, and interactions with other medications.
Limitations
Understanding the genetic underpinnings of complex traits, including those related to aspirin use, is subject to several inherent limitations in current research methodologies. These limitations can impact the power to detect associations, the accuracy of findings, and the generalizability of conclusions across diverse populations.
Methodological and Statistical Constraints
Many genetic studies are constrained by moderate cohort sizes, which can lead to insufficient statistical power to detect modest genetic effects and increase the susceptibility to false negative findings. [3] Conversely, the extensive multiple testing burden in genome-wide association studies (GWAS) means that even seemingly strong associations may represent false positives. [3] These challenges necessitate careful interpretation of reported associations, as they may either obscure true biological signals or highlight spurious ones.
The validation of genetic associations critically relies on successful replication in independent cohorts. [3] However, variations in genotyping platforms and marker sets across studies can impede direct replication at the single nucleotide polymorphism (SNP) level. Different studies might identify distinct SNPs that are in strong linkage disequilibrium with an unknown causal variant, or even multiple causal variants within the same gene, leading to apparent non-replication. [4] Furthermore, the use of imputation to infer missing genotypes, while a necessary practice, introduces potential error rates that can affect the accuracy of findings, particularly for rarer variants. [5]
Phenotypic and Measurement Variability
The precise definition and assessment of phenotypes related to aspirin use, or its various effects and indications, pose significant challenges. When traits are averaged over extended periods, such as two decades, this approach can mask age-dependent genetic influences and introduce misclassification due to changes in measurement equipment over time. [6] Additionally, specific assay limitations, such as an inability to recognize particular genetic variants like the K56M (rs5491) variant of ICAM-1, can lead to the exclusion of relevant individuals from analysis, thereby narrowing the scope of genetic investigation. [1]
Study designs often incorporate specific exclusion criteria, such as removing individuals on certain medications or with particular health conditions, which can impact the generalizability of results. [7] While these exclusions are often necessary to maintain study rigor, they can reduce the effective sample size and introduce cohort bias, making it difficult to extrapolate findings to broader populations or to individuals with co-morbidities common among those who might use aspirin. Furthermore, the adoption of liberal genotyping call rate thresholds, although intended for inclusivity, may introduce lower quality data into analyses, potentially complicating the identification of robust genetic associations. [6]
Generalizability and Confounding Factors
A prominent limitation across many genetic studies is the disproportionate focus on populations of European ancestry. [1] This ancestral bias significantly restricts the generalizability of findings, as the genetic architecture, allele frequencies, and linkage disequilibrium patterns can vary considerably across different ethnic groups. [6] Consequently, genetic insights derived from these studies, particularly those concerning aspirin use or its related outcomes, may not be directly applicable to diverse global populations, leaving substantial gaps in knowledge regarding multi-ethnic applicability.
Genetic variants frequently exert their effects in a context-specific manner, with their influence often modulated by environmental factors. [6] For example, the associations of genes like ACE and AGTR2 with certain physiological traits have been shown to vary according to dietary salt intake. [6] Many studies do not comprehensively investigate these complex gene-environment interactions. This omission means that significant genetic influences on aspirin use or its associated phenotypes might be overlooked or their effects misestimated if environmental confounders are not adequately considered, contributing to remaining knowledge gaps in understanding the full genetic landscape.
Variants
Genetic variations play a crucial role in an individual's predisposition to various health conditions and their response to treatments like aspirin. Variants associated with lipid metabolism, inflammation, and cellular regulation are particularly relevant given aspirin's established roles as an antiplatelet and anti-inflammatory agent. These genetic differences can influence how effectively aspirin might prevent cardiovascular events or manage inflammatory conditions.
Several variants are implicated in lipid metabolism, a key pathway for cardiovascular health. The APOE gene, particularly the rs7412 variant, is central to lipid transport and metabolism, influencing levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP), both markers associated with cardiovascular risk.. [8] Similarly, the rs12740374 variant, located in a region encompassing CELSR2, PSRC1, and SORT1, is strongly associated with LDL and high-density lipoprotein (HDL) cholesterol concentrations.. [8] Another variant, rs583104, near CELSR2 and PSRC1, also contributes to lipid profiles, with the CELSR2-PSRC1-SORT1 locus influencing LDL cholesterol levels.. [5] The LDLR gene, through variants like rs73015016, is vital for clearing LDL from the bloodstream, directly impacting cholesterol levels. Furthermore, the rs28601761 variant in the TRIB1 gene is associated with triglyceride concentrations, highlighting its role in lipid regulation.. [5] Given aspirin's role in preventing cardiovascular disease, individuals with genetic predispositions to adverse lipid profiles might experience differential benefits or considerations for aspirin therapy. [9]
Other variants influence inflammatory and immune responses, which are critical pathways in many diseases where aspirin is used. Variants in the CDKN2B-AS1 gene, such as rs10811654, rs10757274, and rs1831733, are recognized for their roles in cell cycle regulation and inflammation, often linked to conditions like type 2 diabetes and cardiovascular disease. The MICA gene, with variants like rs201838897, and the HLA-B gene, including rs9266361 and rs2523589, are part of the major histocompatibility complex, playing key roles in immune system function and inflammatory processes.. [3] Aspirin's well-known anti-inflammatory effects make these genetic regions particularly interesting for understanding individual responses to the drug, especially in conditions with an inflammatory component. [1]
Beyond lipid metabolism and inflammation, variants in genes like ACAD10 and SMARCA4 contribute to broader metabolic and cellular functions. The rs11066015 variant in ACAD10 is involved in fatty acid metabolism, a fundamental process impacting overall metabolic health. The SMARCA4 gene, represented by rs55997232, encodes a protein crucial for chromatin remodeling, affecting gene expression, cell proliferation, and DNA repair.. [10] These pathways are integral to maintaining cellular homeostasis and preventing disease, and variations within them could influence an individual's susceptibility to conditions where aspirin's pleiotropic effects, beyond its antiplatelet action, might be beneficial. [3]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs10811654 rs10757274 rs1831733 |
CDKN2B-AS1 | colorectal cancer angina pectoris coronary artery disease aspirin use measurement |
| rs11066015 | ACAD10 | esophageal carcinoma coronary artery disease BMI-adjusted waist-hip ratio myocardial infarction fish consumption measurement |
| rs7412 | APOE | low density lipoprotein cholesterol measurement clinical and behavioural ideal cardiovascular health total cholesterol measurement reticulocyte count lipid measurement |
| rs12740374 | CELSR2 | low density lipoprotein cholesterol measurement lipoprotein-associated phospholipase A(2) measurement coronary artery disease body height total cholesterol measurement |
| rs201838897 | MICA | Calcium channel blocker use measurement aspirin use measurement |
| rs9266361 rs2523589 |
HLA-B | Oral ulcer aspirin use measurement BMI-adjusted hip circumference Antithrombotic agent use measurement Calcium channel blocker use measurement |
| rs583104 | CELSR2 - PSRC1 | total cholesterol measurement phospholipid amount, high density lipoprotein cholesterol measurement cholesteryl ester measurement, high density lipoprotein cholesterol measurement lipid measurement, high density lipoprotein cholesterol measurement level of beta-klotho in blood |
| rs55997232 | SMARCA4 | coronary artery disease aspirin use measurement cholesterol to total lipids in small LDL percentage cholesterol to total lipids in medium LDL percentage |
| rs28601761 | TRIB1AL | mean corpuscular hemoglobin concentration glomerular filtration rate coronary artery disease alkaline phosphatase measurement YKL40 measurement |
| rs73015016 | SMARCA4 - LDLR | Antithrombotic agent use measurement aspirin use measurement |
Operational Definition and Research Trait
Aspirin use, within the scope of research studies, is operationally defined as a binary or categorical trait indicating an individual's current or recent engagement in aspirin therapy. This definition serves as a crucial covariate in statistical analyses, especially when examining the associations between genetic variants and various biomarker traits. For instance, studies assessing inflammation and oxidative stress biomarkers, such as CD40 Ligand, C-reactive protein, Interleukin-6, and tumor necrosis factor alpha, consistently adjust for aspirin use due to its well-established anti-inflammatory and antiplatelet properties. [3] Accounting for aspirin therapy in multivariable models is essential to isolate the specific effects of other variables and avoid confounding.
Clinical Context and Therapeutic Classification
Clinically, aspirin is classified primarily as a non-steroidal anti-inflammatory drug (NSAID) with pronounced antiplatelet effects, making it indispensable in cardiovascular medicine. Its therapeutic classification extends to various indications, including primary and secondary prevention of cardiovascular events. A notable example of its clinical application and classification by treatment regimen is its use in cases of suspected acute myocardial infarction, where it may be administered alone or in combination with other antithrombotic agents like heparin. [8] This highlights a nuanced classification that considers not only the presence of aspirin but also its role within broader therapeutic strategies for specific medical conditions.
Terminology and Data Collection Approaches
The terminology used to describe aspirin use in research is generally direct, often appearing as "aspirin" or "aspirin therapy" in covariate lists and participant characteristic tables. Data collection for this trait typically relies on self-report questionnaires, structured interviews, or review of medical records to ascertain whether a participant is taking the medication. [3] While the provided context does not always detail specific dosages or durations, the fundamental operational definition focuses on its presence to control for its systemic impact on measured physiological parameters. This standardized approach ensures consistency in how aspirin's influence is acknowledged across different genetic association studies.
Primary Prevention of Cardiovascular Events
Evidence from randomized clinical trials supports the judicious use of low-dose aspirin for the primary prevention of cardiovascular disease (CVD) . This protective capacity is intricately linked to its ability to modulate inflammatory processes, thereby reducing the overall risk of developing cardiovascular conditions. [7] The use of aspirin in this context highlights its systemic influence on the body's inflammatory responses, contributing to long-term health benefits.
Role in Acute Cardiovascular Events
Beyond primary prevention, aspirin is a critical intervention in the management of acute cardiovascular events, such as suspected acute myocardial infarction. Studies have evaluated its efficacy, both alone and in combination with other anticoagulants like heparin, in improving outcomes for patients experiencing heart attacks. [9] This demonstrates aspirin's immediate therapeutic value in disrupting the pathophysiological processes that lead to coronary artery occlusion and myocardial damage. Its application in emergency settings underscores its rapid-acting effects on blood clotting and vascular inflammation.
Systemic Impact on Inflammation Markers
The efficacy of aspirin in mitigating cardiovascular risk is closely associated with its influence on systemic inflammatory markers. Aspirin's established anti-inflammatory role is relevant to biomarkers such as C-reactive protein (CRP). [7] Elevated CRP levels are indicative of systemic inflammation and are recognized as predictors of cardiovascular disease risk. [7] Although statin therapy is noted to affect CRP levels [11] the broader context of inflammation and its management, which aspirin contributes to, is central to understanding cardiovascular health.
Genetic and Biomolecular Contexts in Cardiovascular Health
The broader biological landscape relevant to aspirin use encompasses various genetic and biomolecular factors that influence cardiovascular health and inflammation. For instance, polymorphisms in the HNF1A gene, encoding hepatocyte nuclear factor-1 alpha, are associated with C-reactive protein levels [12] indicating a genetic influence on systemic inflammation that aspirin aims to counter. Similarly, the HMGCR gene, involved in cholesterol synthesis, has variants affecting LDL-cholesterol levels [13] which are key risk factors for cardiovascular disease where aspirin plays a preventive role. The interplay of these genetic predispositions with environmental factors and therapeutic interventions like aspirin underscores the complex regulatory networks governing cardiovascular health.
Pathways and Mechanisms
Aspirin use is associated with modulating pathways involved in various physiological processes, particularly those related to inflammation and cardiovascular health. [7] While the precise molecular targets of aspirin are not detailed in all contexts, its therapeutic effects are understood to interact with complex biological networks. The following sections outline key pathways and mechanisms relevant to the conditions for which aspirin is utilized, drawing on insights from genetic and metabolic studies.
Regulation of Inflammatory Responses
Aspirin’s therapeutic relevance often stems from its ability to influence inflammatory processes, which are governed by a complex interplay of signaling pathways and regulatory mechanisms. Plasma levels of C-reactive protein (CRP), a widely recognized biomarker for inflammation, are significantly associated with genetic polymorphisms in genes such as HNF1A, LEPR, IL6R, and GCKR . [7], [12] These genes are integral to metabolic syndrome pathways, and their variations can contribute to the dysregulation of the inflammatory state, influencing the progression of chronic inflammatory diseases . [7], [14]
Intracellular signaling cascades, notably the mitogen-activated protein kinase (MAPK) pathway, are central to the cellular response to inflammatory stimuli. [6] Proteins belonging to the human tribbles family are known to control the activity of these MAPK cascades, thereby modulating the strength and duration of inflammatory signals. [15] Furthermore, systemic inflammation is a critical factor in the pathogenesis of conditions like chronic obstructive pulmonary disease (COPD) [16] and the levels of interleukin 6 and its soluble receptor are key components of the broader inflammatory network, with genetic variations impacting the overall inflammatory load in individuals. [17] These intricate molecular interactions collectively highlight the multifaceted regulatory mechanisms that underlie inflammatory responses, which are relevant to the therapeutic scope of aspirin.
Lipid Metabolism and Cholesterol Homeostasis
The management of cardiovascular conditions, a primary area of aspirin use, is intimately linked to the regulation of lipid metabolism and cholesterol homeostasis. The mevalonate pathway, a fundamental metabolic route for the biosynthesis of cholesterol, is tightly regulated by 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). [18] Common genetic variants (SNPs) within the HMGCR gene can influence the alternative splicing of its exon 13, directly impacting the enzyme’s activity and consequently affecting circulating levels of low-density lipoprotein (LDL)-cholesterol. [13] This post-transcriptional regulatory mechanism is a crucial control point in maintaining lipid balance.
Beyond HMGCR, other key genes, such as ANGPTL3 and ANGPTL4, play significant roles in modulating lipid concentrations . [19], [20] ANGPTL3 broadly regulates lipid metabolism, while specific genetic variations in ANGPTL4 are associated with beneficial reductions in triglyceride levels and increases in high-density lipoprotein (HDL). [20] The sterol regulatory element-binding protein 2 (SREBP-2) acts as a vital transcription factor, establishing a link between isoprenoid and adenosylcobalamin metabolism, thereby orchestrating the complex biosynthesis of cholesterol and other essential lipids. [21] These interconnected metabolic and regulatory pathways exemplify the systems-level integration necessary for maintaining lipid homeostasis, which is a critical aspect of cardiovascular health and a target for therapeutic interventions.
Vascular and Cardiac Regulatory Mechanisms
The therapeutic benefits associated with aspirin use in cardiovascular disease underscore the importance of intricate signaling and regulatory mechanisms within the vascular and cardiac systems. For example, the regulation of vascular smooth muscle cells involves cyclic GMP (cGMP) signaling, a pathway that can be antagonized by phosphodiesterase 5 (PDE5). [22] Angiotensin II, a potent vasoconstrictor, has been shown to increase the expression of PDE5A in these cells, which subsequently diminishes cGMP signaling and contributes to the regulation of vascular tone and blood pressure. [23] This mechanism illustrates a significant feedback loop in the control of vascular function.
Furthermore, fundamental electrical processes of the heart, such as cardiac repolarization, are modulated by genetic variants found in genes like NOS1AP (Nitric Oxide Synthase 1 Adaptor Protein). [24] Dysregulation within these pathways can predispose individuals to arrhythmias and other cardiac pathologies. Even ion channels, such as the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) chloride channel, have demonstrated roles in influencing the mechanical properties and cAMP-dependent chloride transport in aortic smooth muscle cells, indicating broader contributions to overall vascular function. [25] These diverse molecular interactions highlight the complex network of regulatory mechanisms that govern cardiovascular physiology and pathology, which are relevant to the context of aspirin's therapeutic applications.
Metabolic Regulation and Disease Risk
Aspirin's broad impact on disease risk extends to conditions characterized by metabolic dysregulation, where specific genetic and metabolic pathways are critically involved. For instance, serum uric acid levels are significantly influenced by genes such as GLUT9 (Glucose Transporter 9) and SLC22A12 (Solute Carrier Family 22 Member 12), which encode transporters responsible for urate excretion . [26], [27] Elevated uric acid is recognized as a significant risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus, indicating its widespread involvement in maintaining metabolic health. [28]
Human metabolic phenotypes exhibit considerable diversity, influenced by a combination of genetic predispositions and environmental factors . [27], [29], [30] The body's capacity for detoxification and the metabolism of various compounds is also crucial, with enzymes such as Glutathione S-transferase omega 1 and omega 2 playing roles in pharmacogenomics and determining the biological fate of chemicals. [31] These regulatory mechanisms, encompassing gene regulation and protein modification, are fundamental to an individual's metabolic profile and their susceptibility to a range of diseases, forming an intricate network of interactions that informs disease prevention and therapeutic strategies.
Genetic Modulators of Aspirin Disposition and Metabolic Phenotypes
The pharmacokinetic profile of aspirin, including its absorption, distribution, metabolism, and excretion, can be significantly influenced by an individual's genetic makeup. Variations in genes encoding drug-metabolizing enzymes are known to affect the "drug metabolism and disposition: the biological fate of chemicals". [31] For instance, pharmacogenomic studies have explored the role of enzymes like _Glutathione S-transferase omega 1_ and _omega 2_ in drug metabolism [31] which could contribute to inter-individual differences in aspirin processing. Such genetic variations can lead to distinct "metabolic phenotypes" [27] dictating how quickly and efficiently an individual metabolizes aspirin into its active and inactive forms, thereby affecting its systemic exposure and potential for therapeutic or adverse effects.
Pharmacodynamic Variability and Aspirin's Antiplatelet and Anti-inflammatory Targets
Aspirin exerts its therapeutic effects primarily through inhibiting cyclooxygenase enzymes, which impacts platelet aggregation and inflammatory pathways. Genetic polymorphisms affecting "hemostatic factors" and "platelet aggregation" [2] can modulate an individual's response to aspirin's antiplatelet action, leading to varied efficacy in cardiovascular event prevention. Beyond its antiplatelet role, aspirin's anti-inflammatory properties are also subject to genetic influence, as evidenced by studies identifying genetic associations with inflammatory biomarkers such as "C-reactive protein" (CRP) [3], [11], [12], [32] and "soluble ICAM-1". [1] For example, polymorphisms in the _HNF1A_ gene are associated with CRP levels [12] suggesting that genetic variants impacting inflammatory responses could alter the effectiveness of aspirin in reducing inflammation.
Clinical Implications for Personalized Aspirin Therapy
Understanding the genetic basis of variability in aspirin's pharmacokinetics and pharmacodynamics holds substantial clinical relevance for optimizing patient care. Differences in drug metabolism and target protein variants can lead to varied "drug efficacy" and "adverse reactions" among individuals. This genetic insight paves the way for "personalized prescribing" [33] strategies, where genetic testing could inform "dosing recommendations" and "drug selection" to achieve optimal outcomes in conditions like acute myocardial infarction, where aspirin is a critical treatment. [9] By identifying individuals who may be rapid or slow metabolizers, or those with altered target sensitivity, clinicians could potentially tailor aspirin therapy to maximize its benefits while minimizing risks, moving beyond a one-size-fits-all approach.
References
[1] Pare G, et al. "Novel association of ABO histo-blood group antigen with soluble ICAM-1: results of a genome-wide association study of 6,578 women." PLoS Genet, 2008.
[2] Yang Q, et al. "Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study." BMC Med Genet, vol. 8, suppl. 1, 2007, p. S12.
[3] Benjamin EJ, et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Med Genet, vol. 8, suppl. 1, 2007, p. S1.
[4] Sabatti, C., et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nature Genetics, vol. 40, no. 12, 2008, pp. 1394-1402.
[5] Willer, C. J., et al. "Newly identified loci that influence lipid concentrations and risk of coronary artery disease." Nature Genetics, vol. 40, no. 1, 2008, pp. 161-169.
[6] Vasan, R. S., et al. "Genome-Wide Association of Echocardiographic Dimensions, Brachial Artery Endothelial Function and Treadmill Exercise Responses in the Framingham Heart Study." BMC Med Genet, vol. 8, 2007, p. S2.
[7] Ridker, P. M., et al. "Loci Related to Metabolic-Syndrome Pathways Including LEPR, HNF1A, IL6R, and GCKR Associate with Plasma C-Reactive Protein: The Women's Genome Health Study." Am J Hum Genet, vol. 82, 2008, pp. 1205–1213.
[8] Kathiresan, S et al. "Common variants at 30 loci contribute to polygenic dyslipidemia." Nat Genet, 2006.
[9] ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. "ISIS-3. a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction." Lancet, 1992.
[10] Melzer, D et al. "A genome-wide association study identifies protein quantitative trait loci (pQTLs)." PLoS Genet, 2008.
[11] Albert, M.A., et al. "Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study." 2001.
[12] Reiner, A. P., et al. "Polymorphisms of the HNF1A Gene Encoding Hepatocyte Nuclear Factor-1 Alpha Are Associated with C-Reactive Protein." Am J Hum Genet, vol. 82, 2008, pp. 1188–1195.
[13] Burkhardt, R., et al. "Common SNPs in HMGCR in Micronesians and Whites Associated with LDL-Cholesterol Levels Affect Alternative Splicing of Exon13." Arterioscler Thromb Vasc Biol, vol. 28, 2008, pp. 1904–1912.
[14] Timpson, N. J., et al. "C-Reactive Protein and Its Role in Metabolic Syndrome: Mendelian Randomisation Study." Lancet, vol. 366, 2005, pp. 1954–1959.
[15] Kiss-Toth, E., et al. "Human Tribbles, a Protein Family Controlling Mitogen-Activated Protein Kinase Cascades." J Biol Chem, vol. 279, 2004, pp. 42703–42708.
[16] Walter, R. E., et al. "Systemic Inflammation and COPD: The Framingham Heart Study." Chest, in press.
[17] Reich, D., et al. "Admixture Mapping of an Allele Affecting Interleukin 6 Soluble Receptor and Interleukin 6 Levels." Am J Hum Genet, vol. 80, 2007, pp. 716–726.
[18] Goldstein, J. L., and M. S. Brown. "Regulation of the Mevalonate Pathway." Nature, vol. 343, 1990, pp. 425–430.
[19] Koishi, R., et al. "Angptl3 Regulates Lipid Metabolism in Mice." Nat Genet, vol. 30, 2002, pp. 151–157.
[20] Romeo, S., et al. "Population-Based Resequencing of ANGPTL4 Uncovers Variations That Reduce Triglycerides and Increase HDL." Nat Genet, vol. 39, 2007, pp. 513–516.
[21] Murphy, C., et al. "Regulation by SREBP-2 Defines a Potential Link between Isoprenoid and Adenosylcobalamin Metabolism." Biochem Biophys Res Commun, vol. 355, 2007, pp. 359–364.
[22] Lin, C. S., et al. "Expression, Distribution and Regulation of Phosphodiesterase 5." Curr Pharm Des, vol. 12, 2006, pp. 3439–3457.
[23] Kim, D., et al. "Angiotensin II Increases Phosphodiesterase 5A Expression in Vascular Smooth Muscle Cells: A Mechanism by Which Angiotensin II Antagonizes cGMP Signaling." J Mol Cell Cardiol, vol. 38, 2005, pp. 175–184.
[24] O'Donnell, C. J., et al. "Genome-Wide Association Study for Subclinical Atherosclerosis in Major Arterial Territories in the NHLBI's Framingham Heart Study." BMC Med Genet, vol. 8, 2007, p. S4.
[25] Robert, R., et al. "Disruption of CFTR Chloride Channel Alters Mechanical Properties and cAMP-Dependent Cl-Transport of Mouse Aortic Smooth Muscle Cells." J Physiol (Lond), vol. 568, 2005, pp. 483–495.
[26] Li, S., et al. "The GLUT9 Gene Is Associated with Serum Uric Acid Levels in Sardinia and Chianti Cohorts." PLoS Genet, vol. 3, 2007, p. e147.
[27] Gieger, C., et al. "Genetics Meets Metabolomics: A Genome-Wide Association Study of Metabolite Profiles in Human Serum." PLoS Genet, vol. 4, 2008, p. e1000282.
[28] Hayden, M. R., and S. C. Tyagi. "Uric Acid: A New Look at an Old Risk Marker for Cardiovascular Disease, Metabolic Syndrome, and Type 2 Diabetes Mellitus: The Urate Redox Shuttle." Nutr Metab (Lond), vol. 1, 2004, p. 10.
[29] Assfalg, M., et al. "Evidence of Different Metabolic Phenotypes in Humans." Proc Natl Acad Sci U S A, vol. 105, 2008, pp. 1420–1424.
[30] Dumas, M. E., et al. "Direct Quantitative Trait Locus Mapping of Mammalian Metabolic Phenotypes in Diabetic and Normoglycemic Rat Models." Nat Genet, vol. 39, 2007, pp. 666–672.
[31] Mukherjee, B., et al. "Glutathione S-Transferase Omega 1 and Omega 2 Pharmacogenomics." Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 34, 2006, pp. 1237–1246.
[32] Pankow, J.S., et al. "Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study." Atherosclerosis, vol. 154, no. 3, 2001, pp. 799-809.
[33] Simon, J.A., et al. "Phenotypic predictors of response to simvastatin African-Americans Caucasians: Cholesterol and Pharmacogenetics (CAP) Study." American Journal of Cardiology, vol. 97, no. 6, 2006, pp. 843-850.